glp-1 gen 5 Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown Join 100 GLP-1 Medications Clinic Near Me
Description
Results of the first phase 3 trial comparing orforglipron with oral semaglutide found that patients with diabetes lost on average 6-8% of their body weight with orforglipron, compared with 4-5% on semaglutide
This is a typical dosing schedule: Starting dose: When you first start taking semaglutide, youll begin with 0.25 milligrams once per week
If you do experience side effects, your provider can offer personalized guidance and resources to help
The primary therapeutic indication for GLP-1 agonists in the UK is type 2 diabetes management, with some formulations also licensed for weight management
